Synthesis and bioassay of β-(1,4)-D-mannans as potential agents against Alzheimer's disease

Abstract

Synthetic homogeneous short chain β-(1,4)-D-mannans shows neuroprotective effect against Aβ peptide toxicity similar to that of heterogeneous oligomannurarate 971 and alzhemed.

A phase II randomized trial of sodium oligomannate in Alzheimer's dementia

“…We realized that our analysis was exploratory and did not survive multiple comparison correction; thus, our ndings should be interpreted with caution. 18 F-FDG-PET data showed that treatment with GV-971 at 900 mg/day slowed the impairment of cerebral glucose metabolism in several AD-associated brain regions. Our results imply that the effects of GV-971 on neuronal function are not simply compensatory in the brain regions affected by AD.…”

“…All results have been expressed as least squares adjusted means and 95% CI. Finally, subjects in the cerebral 18 F-FDG-PET small subgroup underwent PET scanning at baseline and week 24. The relative cerebral metabolic rate for glucose was calculated as the standardized uptake value ratio for the brain regions known to be affected by AD, with the whole brain serving as the reference region.…”

“…The effect of GV-971 on cerebral glucose metabolism, as measured using 18 F-FDG-PET, was evaluated in 7, 9, and 9 patients from the placebo, 600 mg, and 900 mg groups, respectively. Differences, not corrected for multiple comparisons, before and after treatment were noted in the brain regions known to be affected by AD in the 900 mg group, such as the left precuneus (P = 0.0026), right posterior cingulate cortex (P = 0.002), right hippocampus region (P = 0.004), and lower part of the left orbitofrontal gyrus (P = 0.002) ( Fig.…”

“…Moreover, GV-971 can evidently reconstitute the dysbiosis of gut microbiota, reduce metabolite-driven peripheral in ltration of immune cells into the brain, and inhibit neuroin ammation 14 . These effects have been reported to protect synapse integrity and improve cognition in vitro and in a transgenic mouse model of AD [15][16][17][18] .…”

JG6, a novel marine-derived oligosaccharide, suppresses breast cancer metastasis via binding to cofilin

“…With studies continuing to explore the structure-based mechanisms of action of JG6, it is hoped that these results will add impetus to the search for cofilin-targeted carbohydrate-based anti-cancer agents. Our study provides important insights into oligosaccharides as a new and hitherto unrecognized therapeutic class[36]. The unique affinity to proteins of this class of compounds may open new therapeutic opportunities, in particular for those targets challenging to access by small-molecule inhibitors.…”